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The innate immune system (IIS) represents the first line of defense against exogenous 
and endogenous harmful stimuli. Different types of pathogens and diverse molecules 
can activate the IIS via a ligand–receptor mechanism. Cytokine release, recruitment of 
immunocompetent cells, and inflammation constitute the initial steps in an IIS-mediated 
response. While balanced IIS activity can resolve a harmful event, an altered response, 
such as deficient or persistent IIS activity, will have a critical effect on organism homeo-
stasis. In this regard, chronic IIS activation has been associated with a wide range of 
diseases, including chronic inflammatory disorders (inflammatory bowel disease, arthri-
tis, chronic obstructive pulmonary disease, among others), cancer and, more recently, 
neurodegenerative disorders. The relevance of the immune response, particularly inflam-
mation, in the context of neurodegeneration has motivated rigorous research focused on 
unveiling the mechanisms underlying this response. Knowledge regarding the molecular 
hallmarks of the innate immune response and understanding signaling pathway cross 
talk are critical for developing new therapeutic strategies aimed at modulating the neu-
roinflammatory response within the brain. In the present review, we discuss the IIS in the 
central nervous system, particularly the cross talk between the toll-like receptor-signaling 
cascade and the wingless-related MMTV integration site (Wnt) signaling pathway and its 
relevance in neurodegenerative disorders such as Alzheimer’s disease.
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CeNTRAL NeRvOUS SYSTeM (CNS), ALZHeiMeR’S DiSeASe 
(AD), AND THe iMMUNe ReSPONSe: GeNeRAL 
CONSiDeRATiONS
The CNS constitutes a highly specialized structure with neuronal physiology depending on the ful-
fillment of specific microenvironmental requirements, which are necessary to control the molecular 
and cellular efflux/influx between the CNS and blood (1–3). This controlled isolation, which is 
mainly established by the blood–brain barrier (BBB), initially led to the idea that the CNS was 
deprived of immune cells, although its ability to respond to systemic and localized pathological 
conditions have not only demonstrated its capacity to exhibit an immune response but has also 
allowed the identification of specific cells that are responsible for this function (4). Within the brain, 
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microglia and astrocytes are specialized cells that function in 
immune surveillance and response against several pathological 
conditions (4–8). Importantly, common systemic immune cells, 
such as cluster of differentiation 11b and c (CD11b, CD11c)-
positive cells, can be found in the CNS during the brain immune 
response, and these factors mainly localize close to BBB-damaged 
areas, suggesting that their migration from the periphery and 
colonization of the CNS are due to an increase in BBB perme-
ability (4, 9–12). However, it has been recognized that the brain 
parenchyma constitutes an anti-inflammatory environment that 
is rich in anti-inflammatory mediators, such as transforming 
growth factor β (TGFβ) and interleukin (IL)-10, which prevent 
peripheral immune cell proliferation (13–15), providing further 
support to the hypothesis that glial cells within the brain are 
responsible for the IIS response. Although it is possible that these 
characteristics are evidence of an immune-incompetent organ, 
Ransohoff and Brown (15) proposed that these particularities 
appear to be necessary to avoid strong immune responses, which 
can further damage neurons. Consequently, even when the 
protective role of the IIS is not considered, the balance of the 
immune response is critical within the CNS to prevent additional 
damage. Importantly, this balance is dependent on both signals 
to unleash the immune response. However, how CNS competent 
cells interpret these signals, including the molecular mechanisms 
triggered as a part of this response, remains to be determined.
The immune response and the inflammatory component of 
such a response are most relevant in several neurodegenerative 
disorders, including AD, Parkinson’s disease, Huntington’s dis-
ease, multiple sclerosis, and amyotrophic lateral sclerosis. Indeed, 
the broad molecular alterations verified during the course of 
these pathologies have identified the inflammatory response as a 
critical element for consideration at different stages of the disease. 
Consistent with these findings, many efforts have committed not 
only to understand the inflammatory response within the brain 
or the CNS but also to identify new molecular targets that can 
modulate the inflammatory process. Thus, in the present review, 
we describe some of the particularities of the toll-like receptors 
(TLRs) and the molecular mechanisms triggered after their acti-
vation, as well as their close relationship with the wingless-related 
MMTV integration site (Wnt) signaling pathway. Similarly, we 
summarize some of the relevant scientific evidence suggesting 
that the cross talk between TLR and Wnt signaling plays a relevant 
role in neurodegenerative disorders, particularly in AD.
AD and Neuroinflammation
According to Alzheimer’s Disease International, AD is the 
leading cause of dementia, accounting for up to 50–75% of all 
dementia cases worldwide. With a total estimated cost of up 
to $818 billion, AD is a worldwide public health issue (https://
www.alz.co.uk/research/WorldAlzheimerReport2015.pdf ). 
Many human and financial efforts have been committed to 
understanding this pathology in an attempt to prevent, slow, stop, 
and/or reverse AD, which was first described in the early 1900s. 
Although relevant progress has been made through the years, 
our knowledge remains incomplete, and no effective therapy 
is currently available to treat this pathology. Clinically, AD is 
characterized by progressive cognitive impairment with mood 
and behavioral alterations. Memory loss worsens as pathology 
progresses, reflecting brain atrophy as a consequence of severe 
neuronal loss (16–20). However, extracellular amyloid-β peptide 
(Aβ) aggregates, also known as senile plaques, and intracellular 
neurofibrillary tangles (NFTs) consisting of hyperphosphoryl-
ated tau protein are the molecular hallmarks of the disease and 
are considered the basis of the molecular alterations leading to 
neuronal death (20–22). Moreover, according to the amyloid 
hypothesis of AD, Aβ constitutes the starting point for all altera-
tions observed during disease progression, including the NFTs, 
and although the triggering mechanisms leading to increased Aβ 
production and aggregation have not yet been elucidated, our 
understanding of the Aβ effects on the cell molecular machinery 
has improved significantly (23–27). Increased production of 
reactive oxygen species (ROS), mitochondrial dysfunction, NFT 
formation, increased Aβ production, and synaptic disruption are 
some of the consequences of exposure to Aβ (28, 29). However, 
in recent years, the Aβ-related inflammatory component of the 
pathology has become significantly relevant and is considered a 
critical target to control AD (30). Moreover, it has been suggested 
that permanent exposure to Aβ due to an increased production 
or a deficient clearance mechanism from the brain will lead to a 
chronic inflammatory state, which results in a harmful environ-
ment for the neurons, causing additional damage and ultimately 
further neuronal death (3, 30). Furthermore, the inflammatory 
mechanisms triggered by Aβ are driven mostly through the TLR 
family.
TOLL-LiKe ReCePTORS
As the first unspecific defense, the IIS functions to sense both 
molecular patterns related to pathogenic presence (pathogen-
associated molecular patterns, PAMPs) and molecular patterns 
related to endogenous molecules indicative of cell damage 
(damage-associated molecular patterns, DAMPs) via specific 
receptors known as pattern recognition receptors (PRRs) (5, 
6, 31, 32). The TLR family constitutes a highly relevant type of 
PRR that is necessary not only to unleash the initial immune 
response but also to connect this first unspecific defense with 
secondary adaptive immunity (6). The presence of TLRs has been 
determined in several cell components of the peripheral immune 
system and in immunocompetent cells of the brain, such as astro-
cytes and microglia, as well as in neurons and oligodendrocytes 
(5, 6), suggesting that each cell type within the brain can sense 
and react to harmful molecular patterns. It has also been demon-
strated, with some discrepancies between studies, that microglia 
and neurons express all TLR subtypes, while astrocytes express 
a more limited repertoire, including TLR2, TLR3, TLR4, TLR9, 
and TLR11 (33, 34).
Several members of the TLR family have been described, 
ranging from 11 to 13 subtypes and depending on the species 
(5). According to Hanke and Kielian (6), TLRs can be divided 
into two main groups: those expressed on the plasma mem-
brane, such as TLRs 1, 2, 4, 5, and 6, and those expressed on 
endosomes, such as TLR 3, 7, 8, and 9. In addition, TLRs 1, 2, 4, 
and 6 recruit an adaptor protein known as cluster of differentia-
tion 14 (5, 6). While external TLRs sense bacterial proteins, such 
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as lipopolysaccharide, flagellin and lipoproteins, internal TLRs 
sense viral components, such as viral RNA and DNA, as well as 
non-methylated CpG-enriched DNA (6, 15, 31). Importantly, 
TLRs consist of a toll/interleukin-1 (TIR) intracellular domain, 
which, once ligand-activated, triggers the molecular cascade 
necessary for an immune/inflammatory response (5). TLRs 
usually signal through the myeloid differentiation factor 88 
(MyD88) pathway. Accordingly, MyD88 recruitment leads to the 
activation of interleukin-1 receptor-associated kinase (IRAK) 
family of proteins, which in turn results in the activation of 
tumor necrosis factor receptor-associated factor 6, causing the 
recruitment of transforming growth factor-β-activated kinase-1 
(TAK1). TAK1 along with TAK1-binding proteins activate the 
IKK complex, resulting in the phosphorylation of IκB factor, 
which induces the release of nuclear factor-κB (NF-κB) and ena-
bles its translocation to the nucleus and subsequent expression 
of inflammatory-related genes (Figure 1) (5, 35, 36). However, 
some TLRs, such as TLRs 3 and 4, can signal via an additional 
pathway mediated by TIR-containing adaptor inducing 
interferon-β (IFN-β) (TRIF). Although this pathway results in 
the release of NF-κB, it also causes, via the IKKε/TANK-binding 
kinase-1 (TBK1), the phosphorylation of interferon regulatory 
factor 3 and 7 (IRF3-7), inducing IFN-β expression (35, 36). At 
the end of these TLR-related molecular cascades, we observe 
the production and release of several molecular mediators, such 
as cytokines, chemokines, complement proteins, and enzymes, 
including IL-1, IL-6, IL-10, IL-11, IL-12, tumor necrosis factor 
(TNF), TGF, IFN, CCL2, CCL5, CXCL8, and CXCL10, among 
others (4–6, 15, 35, 36).
Although these mechanisms are the basis of the molecular 
effects following TLR activation, it is necessary to consider some 
additional features of the TLR signaling cascade. Taking these 
findings into consideration, TAK1 activation not only activates 
the IKK complex but also activates the nemo-like kinase (NLK) 
(37, 38) as well as the c-Jun N-terminal kinases (JNK) pathway 
(Figure  1) (35, 36). Similarly, it has been demonstrated that 
MyD88 can signal through the phosphatidylinositide-3 kinase 
(PI3K)/Akt pathway, leading to modulation of glycogen syn-
thase kinase 3 β (GSK3β) activity (39, 40). Moreover, it has been 
suggested that some members of the TLR family, such as TLR2 
and TLR4, can also activate the PI3K/Akt pathway via a direct 
interaction with the Ras-related C3 botulinum toxin substrate 1 
(Rac1), a member of the Rho family of GTPases (40). However, it 
is well recognized that the Janus kinase (JAK)/signal transducer 
and activator of transcription (STAT) (JAK/STAT) pathway 
respond to a variety of PAMPs/DAMPs and cytokines, including 
different interleukins and INF-β. However, studies performed 
by Luu and colleagues (41), and more recently, the work of Song 
and colleagues (42), have demonstrated that several members 
of the TLR family can phosphorylate different STAT members, 
suggesting a direct modulation of the JAK/STAT pathway 
(Figure 1).
Although we will further discuss the wide signaling pathway 
involvement, it is important to highlight that an immune response 
usually triggers the release of inflammatory-related molecules, 
which can act via both autocrine and paracrine mechanisms. 
Thus, an immune response cannot be considered a linear event, 
but rather, it should be considered as a cyclic process in which 
the initial cellular response causes the production and release 
of secondary molecules that can affect both the same cell and 
neighboring cells. INF-β is a good example of such a situation. 
As previously indicated, TLR3 and TLR4 can induce IFN-β 
production via IRF phosphorylation, and this IFN-β can interact 
with the interferon receptors (INFGR1 and INFGR2), resulting 
in activation of the JAK/STAT pathway and inducing the expres-
sion of further inflammatory-related genes (43, 44). This example 
exemplifies the complex molecular interactions established dur-
ing an immune response, and in the following sections, we will 
highlight the elements that connect the TLR-mediated immune 
response with the Wnt signaling pathway, a critical molecular 
cascade in the developing and mature CNS in both physiological 
and pathological conditions.
Aβ- and TLR-Mediated immune/
inflammatory Response
Aβ is a short sequence of 36–43 amino acids that reacts with 
several biological molecules, including lipids and proteins, which 
also form Aβ aggregates (23, 45). Although the most common 
form is Aβ40, Aβ42 is considered to be more reactive and more 
prone to aggregation (46–49). Aβ has been demonstrated to 
interact with several members of the TLR subfamily of receptors, 
including TLR2 and TLR4, inducing an immune response with 
the subsequent release of pro-inflammatory molecules, including 
several members of the IL family, such as IL-1β, IL-6, IL-12, TNFα, 
cyclooxygenase 2, and inducible nitric oxide synthase (4, 46, 48, 
50, 51). Importantly, as inflammatory mediators, these molecules 
can further induce a TLR-mediated immune response, and as 
previously indicated, because microglia, astrocytes, neurons, 
and oligodendrocytes express several members of this family of 
receptors, it is possible to suggest that these cells are not only able 
to respond to the Aβ challenge but they may also respond to the 
inflammatory mediators released in response to that initial insult. 
Indeed, it has been demonstrated that IL-6 levels are significantly 
elevated in AD, and its increased expression can be achieved 
via both direct production after primary insult on microglia, 
astrocytes, and/or neurons or as a secondary response to pro-
inflammatory mediators such as IL-1β (52–56). Although in a 
coordinated response there are compensatory mechanisms such 
as the production of IL-10 and TGFβ that prevent an exacerbated 
immune response, under chronic pro-inflammatory conditions, 
similar to conditions of permanent exposure to Aβ in AD, the 
system will be unbalanced, resulting in an increased production 
of pro-inflammatory mediators, which worsen the pathological 
scenario (57). Moreover, it is well established that in the case of 
microglia, pro-inflammatory signals trigger the activation of this 
cell, with the subsequent release of additional pro-inflammatory 
mediators, while the presence of anti-inflammatory molecules 
(IL-10 and TGFβ) leads to an anti-inflammatory microglial state 
with the release of neurotrophic factors such as brain-derived 
neurotrophic factor and glial-derived neurotrophic factor. These 
factors serve to repair the damage induced initially (57–59). In 
this regard, it has been demonstrated that activated microglia 
surround the Aβ aggregates within the brain, suggesting a 
FiGURe 1 | TLR molecular cascade. Upon activation, TLRs can signal through different transduction molecules. The MyD88-mediated pathway constitutes the 
classical TLR signaling pathway and ultimately leads to the activation of the NF-κB transcription factor, resulting in the production and release of pro-inflammatory 
mediators. In addition, some members of the TLR family can activate other pathways, such as PI3K and JAK/STAT. Although these mechanisms also lead to NF-κB 
activation, the intermediary molecular nodes can interact and activate additional signaling pathways. TLR, toll-like receptor; MyD88, myeloid differentiation factor 88; 
TAK1, transforming growth factor-β-activated kinase-1; IKK, inhibitory NF-κB kinases; NLK, nemo-like kinase; JNK, c-Jun N-terminal kinases; NF-κB, nuclear 
factor-κB; TRIF, TIR-containing adaptor inducing interferon-β; PI3K, phosphatidylinositide-3 kinase; Akt, protein kinase B; GSK3β, glycogen synthase kinase 3 β; 
JAK, Janus kinase; STAT, signal transducer and activator of transcription.
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permanent pro-inflammatory state that contributes to the spread 
of the pro-inflammatory environment across the brain (60–62).
Similarly, another feature that must be considered is the mito-
chondrial dysfunction induced by Aβ. This alteration will not 
only alter the energy balance within the neurons due to impaired 
ATP production but will also induce an increase in ROS levels, 
resulting in the production of additional pro-inflammatory 
mediators, such as IL-6 (63–66). In addition, once released to the 
extracellular compartment, ROS can further activate the inflam-
matory pathways in neighboring cells inducing the activation of 
the NF-κB-dependent pro-inflammatory cascade (67, 68).
Importantly, the inflammatory cascade occurs within a com-
plex cellular molecular network, and under such conditions, it is 
not difficult to realize that the interaction between the different 
molecular pathways within the cell is a fundamental feature of 
the coordinated response against different stimuli. Based on 
our experience and on the current knowledge regarding neu-
roinflammation, in the following section, we will describe and 
discuss the Wnt signaling pathway and its relationship with the 
TLR-mediated immune/inflammatory response.
wnt SiGNALiNG PATHwAY
Initially described in Drosophila, the Wnt glycoproteins currently 
constitute a relevant molecular system related to critical physi-
ological events, including cell proliferation and differentiation 
(69–71). Wnt proteins are highly conserved among different 
species; in mammals, up to 19 members have been identified (7). 
Moreover, beyond its physiological roles, several studies, includ-
ing some conducted by our laboratory, have demonstrated the 
involvement of this family of proteins in pathological processes 
of the CNS, such as neurodegenerative disorders (71–76). These 
Wnt proteins can activate two main pathways: the canonical and 
non-canonical Wnt pathways (77) (Figure 2).
In the canonical or β-catenin-dependent pathway, Wnt 
proteins bind to the Frizzled receptor/low-density lipoprotein 
receptor-related protein 5/6 (Fz/LRP5/6), inducing the activation 
of the disheveled protein and the interaction between LRP5/6 with 
Axin. This interaction causes the disassembly of the β-catenin 
destruction complex consisting of adenomatous polyposis coli, 
Axin, GSK3β, and casein kinase-1, preventing GSK3β-mediated 
FiGURe 2 | General overview of the wnt signaling pathway. The Wnt signaling pathway can be divided into the canonical Wnt signaling and non-canonical 
Wnt pathways. During activation, canonical Wnt ligands interact with the Fz-LRP5/6 complex receptor, inducing the activation of Dvl and the recruitment of Axin by 
LRP5/6. This situation leads to the disassembly of the β-catenin destruction complex, which prevents GSK3β-mediated β-catenin phosphorylation. Thus, β-catenin 
can translocate to the nucleus where it binds to the TCF/Lef, initiating the transcription of Wnt-related genes. When inactivated, the β-catenin destruction complex 
remains stabilized, allowing the phosphorylation of β-catenin, inducing its degradation by the proteasome. However, the non-canonical Wnt/PCP pathway requires 
non-canonical Wnt ligands, which will interact with the Fz receptor and will activate Dvl. However, at this point, Dvl induces the activation of RhoA and Rac, which 
ultimately will lead to cytoskeletal rearrangement. Similarly, a secondary non-canonical Wnt pathway, known as Wnt/Ca2+, can be triggered by non-canonical Wnt 
ligands. In this case, Fz will induce the release of calcium from intracellular stores, leading to the activation of calcineurin, CamKII, and PKC. Fz, frizzled receptor; 
LRP, low-density lipoprotein receptor-related protein; Dvl, disheveled; APC, adenomatous polyposis coli; GSK3β, glycogen synthase kinase 3 β; TCF/Lef, T-cell 
factor/lymphoid enhancer factor; PCP, planar cell polarity; RhoA, Ras homolog gene family member A; ROCK, rho-associated protein kinase; Rac1, Ras-related C3 
botulinum toxin substrate 1; JNK, c-Jun N-terminal kinase; PKC, protein kinase C; CamKII, calcium/calmodulin kinase II.
5
Zolezzi and Inestrosa Wnt/TLR Cross Talk in Neuroinflammation
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 187
β-catenin phosphorylation. Next, β-catenin can translocate to the 
nucleus and bind to the T-cell factor/lymphoid enhancer factor 
(TCF/Lef) transcription factor to induce Wnt gene expression. 
In the absence of Wnt proteins, the destruction complex remains 
active and promotes GSK3β-mediated β-catenin phospho-
rylation, resulting in proteasomal degradation of β-catenin and 
blockade of the expression of Wnt target genes (77–79). However, 
the non-canonical Wnt pathway can be further divided into two 
additional mechanisms: the Wnt/planar cell polarity (Wnt/PCP) 
pathway, which requires the binding of Wnt proteins to the Fz 
receptor to activate disheveled and subsequently Rho and Rac 
GTPases, inducing JNK activity and leading to actin cytoskeleton 
modeling (7, 71, 80), and the Wnt/Ca2+ pathway in which the 
binding of Wnt proteins to the Fz receptor causes the release of 
Ca2+ from intracellular compartments, inducing the activation of 
calcium-related proteins, such as protein kinase C and calcium/
calmodulin-dependent protein kinase (Ca2+/CamKII) (7, 71, 81).
According to Marchetti and Pluchino (7), Wnt proteins can be 
categorized according to their ability to induce a specific pathway 
into two main classes: the Wnt1 subtype, which includes Wnt2, 
-3, -3a, and -8a; and the Wnt5a subtype, which includes Wnt4, 
-5a, -5b, -6, -7a, and -11. However, this classification states that 
the Wnt1 subfamily activates the canonical Wnt pathway, while 
Wnt5a functions via non-canonical signaling, and in some cases, 
the same Wnt ligand can activate both pathways depending on 
the physiological/pathological conditions (7). Moreover, it has 
been established that beyond the external regulation of the Wnt 
pathways by ligands and inhibitors, the cross talk between both 
canonical and non-canonical signals can exert a modulatory 
effect over its counterpart. Furthermore, Wnt pathways also 
interact with additional signaling pathways, including NF-κB, 
forkhead box O, Notch, hypoxia-inducible factor 1α, and JNK 
(28, 82). In this regard, several elements of the Wnt cascade con-
stitute molecular master switches that can be accessed through 
additional signaling pathways. GSK3β, TCF/Lef transcription 
factor, and β-catenin are examples of Wnt elements that are able 
to receive input from additional signaling cascades, which can 
have a modulatory effect on Wnt pathways. Importantly, these 
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characteristics demonstrate the critical role that Wnt pathways 
play in several cellular processes, including the pathophysiologi-
cal mechanisms verified during the development of several CNS 
disorders, such as neurodegenerative diseases.
wnt SiGNALiNG AND TLR CROSS TALK: 
TOwARD NeUROiNFLAMMATORY 
MODULATiON
Controlling the immune/inflammatory response in the context of 
AD has emerged as a fundamental goal to successfully approach 
treating this disease. However, a general anti-inflammatory drug 
is not sufficient to resolve the problem, as different interventions 
are needed to modulate such a response within the CNS. In this 
regard, the Wnt signaling pathway, which has demonstrated 
relevant functions in several cell physiological processes, has also 
important functions as an immune/inflammatory modulator (7, 
28, 83).
Currently, it is commonly accepted that canonical Wnt sign-
aling acts as an anti-inflammatory mechanism, while the non-
canonical pathway has pro-inflammatory activity (7, 28). Several 
studies have demonstrated the anti-inflammatory activity of the 
canonical Wnt pathway, and among the mechanisms that explain 
this effect, the direct interaction with members of the NF-κB 
transcription factor family, such as RelA, constitutes a relevant 
mechanism (28, 84, 85). Furthermore, blockade of the canonical 
Wnt pathway has been demonstrated to promote an inflamma-
tory state, at least in lungs exposed to silica (86). However, activa-
tion of the non-canonical Wnt pathway has been demonstrated 
to promote inflammation and induce the pro-inflammatory state 
of microglia and to amplify the neuroinflammatory environment 
caused by Aβ exposure (7, 84, 87). Similarly, through different 
pathways, including PI3K/Akt, Rac1, and MAPK, non-canonical 
Wnt ligands induce the activity of the NF-κB transcription factor 
(88) (Figure 3). However, the non-canonical ligand Wnt5a has 
also been observed to exert anti-inflammatory activity upon LPS 
challenge or in bone tissue, and canonical Wnt ligands can induce 
the pro-inflammatory state in previously activated microglia 
(89–91). As previously indicated, this situation only confirmed 
that the physiological and cellular context is important when 
deciphering the outcome of Wnt pathway activation.
Considering that Wnt pathways can affect the activity of the 
NF-κB transcription factor, a common end point and a master 
controller of the TLR-mediated response, the cross talk between 
the Wnt and TLR pathways appears to be evident (28). However, at 
this point, some key molecular elements, previously highlighted 
in the present work, allow the establishment of a closer interplay 
between the molecular components of both signaling pathways.
Toll-like receptor activation has been demonstrated to down-
regulate the canonical Wnt signaling pathway. Indeed, TLR4 
activation has been shown to prevent LRP6 phosphorylation, 
which is necessary for Fz-LRP5/6 activity, and block the canoni-
cal Wnt signaling at the early steps of the molecular cascade 
(92) (Figure  3A). However, in macrophages, activation of the 
non-canonical Wnt pathway, Wnt/Ca2+, by the Wnt5a ligand 
can induce, in a TAK1-dependent manner, the expression of 
the suppressor of cytokine signaling 1 and of protein inhibitors 
of activated STAT 1, which causes a decrease in the expression 
levels of several signal transducers of the TLRs cascade, such 
as IRAK members and MyD88 (93) (Figure 3B). However, the 
precise mechanisms of TLR-mediated up-/downregulation of 
Wnt signaling and vice versa, or if these regulatory mechanisms 
are confirmed in microglia, astrocytes, and/or neurons, comprise 
an open field for future research.
Conversely, the MyD88-mediated TLR activity results in 
TAK1 activation of NLK (Figure  1), which directly interacts 
with Wnt signaling pathways at the level of the β-catenin-TCF/
Lef complex (94) (Figure  3A). Controversially, it has been 
demonstrated that NLK can positively and negatively regulate 
canonical Wnt signaling. Indeed, while Ota and colleagues (95) 
have demonstrated that NLK favors the expression of canonical 
Wnt target genes via Lef phosphorylation, Ishitani and colleagues 
(96) previously demonstrated a coordinated interaction between 
TAK1-NLK and the Wnt/Ca2+ pathway to antagonize canonical 
Wnt signaling. Once again, the cell and physiological contexts 
appear to be determinants for the outcome of such an interaction.
In a similar manner, TLRs, through PI3K, can induce the 
activation of Akt, a critical kinase able to phosphorylate GSK3β 
(97). Moreover, it has recently been demonstrated that MyD88-
independent TLR signaling activates IKKε/TBK1, which can 
directly phosphorylate Akt, leading to GSK3β inhibition (98). 
Importantly, GSK3β constitutes a key protein in the canonical 
Wnt pathway as its activity induces β-catenin degradation. 
Consequently, Akt-mediated inhibition of GSK3β can lead to 
increased activity of the canonical Wnt pathway due to increased 
levels of stabilized β-catenin, which translocates to the cell nucleus 
(97) (Figure 3A). In addition, GSK3β activity has also been dem-
onstrated to be relevant for TLR-mediated cytokine production. 
Indeed, inhibition of GSK3β impairs the ability of NF-κB to bind 
to the cAMP response element-binding protein (CREB)-binding 
protein (28, 85, 97). Interestingly, it has also been suggested that 
this impairment could be mediated by the nuclear β-catenin 
(Figure 3B). Further confirmation of this interaction mediated 
through the GSK3β node is provided by studies performed by 
Li and colleagues (99) on the effects of lithium, a well-known 
canonical Wnt signaling agonist, which induces the inhibition of 
GSK3β. In that study, the authors observed that lithium not only 
reduces the expression of pro-inflammatory mediators, such as 
IL-6, but it also reduces TLR4 expression in astrocytes. Whether 
these effects are mediated directly by Wnt signaling or as a part of 
a secondary mechanism, the convergence around GSK3β further 
supports the idea that a direct interplay between these pathways 
is part of the immune/inflammatory response.
FiNAL CONSiDeRATiONS
The immune response constitutes a highly complex mechanism 
that involves the interaction between several signaling pathways 
within different cell types. Inflammation is a component of 
the coordinated immune response, and within the CNS, it has 
emerged as a critical element because a sustained inflammatory 
state can further damage the neuronal network. Aβ, an AD 
molecular hallmark, induces an inflammatory response via a 
FiGURe 3 | Proposed molecular talking points between TLRs, wnt, and nuclear factor-κB (NF-κB). The schematic summarizes the suggested interplaying 
molecular nodes between the different signaling pathways addressed in the present review. (A) According to the literature, TLRs can modulate the activity of Wnt 
signaling at different points. TLRs can prevent the activation of LRP6, supporting the function of the β-catenin destruction complex, thereby promoting the 
degradation of β-catenin and blocking the expression of Wnt target genes. In contrast, TLRs can lead, through PI3K and IKKε, to the activation of Akt, causing the 
inhibition of GSK3β. However, TLR signaling can also lead to NLK activation, which can interact with the Lef member of the TCF/Lef transcription factor. (B) Similarly, 
Wnt signaling, through its different pathways, can modulate the activity of the TLRs. The non-canonical Wnt/Ca2+ pathway can induce, through TAK1, the activation 
of SOC1 and PIAS1, causing a reduced expression of TLR signal transducers, such as Myd88. Similarly, the non-canonical Wnt/PCP can interact through Rac1/
PI3K/Akt with the IKK complex, modulating the activation of NF-κB. In the case of canonical Wnt signaling, direct modulation of the NF-κB through a Wnt-mediated 
RelA interaction has been demonstrated. Moreover, it has been suggested that β-catenin can block the interaction between NF-κB and CBP/P300, preventing the 
transcription of NF-κB-target genes. TLR, toll-like receptor; MyD88, myeloid differentiation factor 88; TAK1, transforming growth factor-β-activated kinase-1; IKK, 
inhibitory NF-κB kinase; NLK, nemo-like kinase; PI3K, phosphatidylinositide-3 kinase; Akt, protein kinase B; LRP6, low-density lipoprotein receptor-related protein 6; 
GSK3β, glycogen synthase kinase 3 β; TCF/Lef, T-cell factor/lymphoid enhancer factor; PCP, planar cell polarity; Rac1, Ras-related C3 botulinum toxin substrate 1; 
SOC1, suppressor of cytokine signaling 1; PIAS1, protein inhibitors of activated STAT 1; CBP, CREB-binding protein, RelA, p65 subunit.
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TLR-mediated mechanism, and continuous exposure to Aβ 
perpetuates the pro-inflammatory state. Consistent with these 
findings, modulation of the inflammatory response is considered 
a major goal to limit the damage observed in AD. In this regard, 
the canonical and non-canonical Wnt signaling pathways have 
demonstrated both pro- and anti-inflammatory activity; how-
ever, the precise mechanisms of such a modulatory role are far 
from clear. During the last decade, several research groups have 
found relevant evidence suggesting a direct interaction between 
the Wnt pathways and the TLR-mediated immune response, and 
although further research is needed to elucidate some controver-
sies observed regarding this interaction, the current knowledge 
suggests that cross talk between these two molecular cascades can 
provide insight toward new therapeutic targets in the context of 
neurodegenerative disorders, such as AD.
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